# US 8,278,060 B2 · Use of VEGF-D in the diagnosis of lymphangioleiomyomatosis (LAM) disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,060 B2
- Document ID: US8278060B2
- Status: Granted
- Kind: B2
- Application number: 13/242,288
- Filed: 2011-09-23
- Published: 2012-01-12
- Granted: 2012-10-02
- Earliest claimed: 2007-12-05
- Assignees: Children's Hospital Medical Center University of Cincinnati
- Inventors: Francis X. McCormack; Lisa R. Young
- Web page: https://patentgrep.com/patent/US8278060B2

## CPC

- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- A61B 5/415: {the glands, e.g. tonsils, adenoids or thymus}
- A61B 5/416: {the spleen}
- A61B 5/418: {lymph vessels, ducts or nodes}
- A61B 5/08: Measuring devices for evaluating the respiratory organs
- A61B 6/03: Computed tomography [CT]
- G01N 2333/52: Assays involving cytokines
- G01N 2800/12: Pulmonary diseases
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)

## Abstract

Described herein are methods of diagnosing lymphangioleiomyomatosis (LAM) that permits differentiating LAM from another lung disorder. Methods of treatment are also provided.

## Claims

### Claim 1

A method of treating lymphangioleiomyomatosis (LAM) in a human subject comprising
(a) diagnosing a subject as having LAM by a method that comprises measuring VEGF-D concentration in a biological sample from the subject, wherein an elevated VEGF-D concentration in the sample compared to a predetermined criterion is indicative of LAM in the subject, wherein the predetermined criterion comprises VEGF-D measurements from a plurality of human subjects with tuberous sclerosis complex (TSC) or a cystic or chylous lung disorder that are free of LAM, wherein an elevated level of VEGF-D in the sample compared to the VEGF-D measurements from the human subjects that are free of LAM, is diagnostic of LAM; and
(b) administering a standard of care therapeutic to the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the predetermined criterion further comprises
VEGF-D measurements from a plurality of human subjects that have LAM, wherein a level of VEGF-D in the sample that corresponds to the VEGF-D measurements from the human subjects that have LAM, is diagnostic of LAM.

### Claim 3

A method of treating lymphangioleiomyomatosis (LAM) in a human subject comprising
(a) diagnosing a subject as having LAM by a method that comprises measuring VEGF-D concentration in a biological sample from the subject, wherein an elevated VEGF-D concentration in the sample compared to a predetermined criterion is indicative of LAM in the subject, wherein the predetermined criterion is a receiver operating characteristic curve based on data of VEGF-D measurements in subjects with LAM and subjects with TSC or a cystic or chylous lung disorder that are free of LAM; and
(b) administering a standard of care therapeutic to the subject.

### Claim 4

A method of treating lymphangioleiomyomatosis (LAM) in a human subject comprising
(a) diagnosing a subject as having LAM by a method that comprises measuring VEGF-D concentration in a biological sample from the subject, wherein an elevated VEGF-D concentration in the sample compared to a predetermined criterion is indicative of LAM in the subject, wherein the predetermined criterion is a cutoff value of VEGF-D concentration, wherein the cutoff value is determined, based on previous measurements to discriminate LAM with a sensitivity and specificity calculated from measurements of VEGF-D in human subjects with LAM and human subjects with TSC or a cystic or chylous lung disorder that are free of LAM; and
(b) administering a standard of care therapeutic to the subject.

### Claim 5 (depends on 4)

The method of claim 4, wherein the measurement of VEGF-D is a serum concentration, and the cutoff value is about 574 pg/mL.

### Claim 6 (depends on 4)

The method of claim 4, wherein the measurement of VEGF-D is a serum concentration, and the cutoff value is about 750 pg/ml.

### Claim 7 (depends on 1)

The method of claim 1, wherein the measuring comprises contacting the sample with a VEGF-D antibody under conditions that allow binding of the antibody to VEGF-D in the sample.

### Claim 8 (depends on 7)

The method of claim 7, wherein the measuring further comprises quantitatively determining the amount of antibody-VEGF-D complex formed.

### Claim 9 (depends on 7)

The method of claim 7, wherein the antibody is a monoclonal antibody.

### Claim 10 (depends on 7)

The method of claim 7, wherein the antibody is immobilized on a solid support.

### Claim 11 (depends on 7)

The method of claim 7, wherein an ELISA assay is used to measure the VEGF-D.

### Claim 12 (depends on 7)

The method of claim 7, wherein the antibody is labeled, and the amount of VEGF-D is determined my measuring the amount of label in antibody-VEGF-D complex.

### Claim 13 (depends on 1)

The method of claim 1, wherein the biological sample comprises serum.

### Claim 14 (depends on 1)

The method of claim 1, wherein LAM is selected from the group consisting of tuberous sclerosis complex lymphangioleiomyomatosis (TSC-LAM) and non-heritable sporadic form lymphangioleiomyomatosis (S-LAM).

### Claim 15 (depends on 1)

The method of claim 1, wherein the subject is female.

### Claim 16 (depends on 1)

The method of claim 1, wherein the standard of care therapeutic is selected from the group consisting of hormone therapy, oxygen therapy, pleurodesis, embolization, ablation or resection of angiomyolipomas; bronchodilator therapy, withdrawal from estrogen-containing medications, thoracic duct ligation, oophorectomy and lung transplantation.

### Claim 17 (depends on 16)

The method of claim 16, wherein the standard of care therapeutic is a hormone selected from the group consisting of progestins and gonadotropin releasing hormone.

### Claim 18 (depends on 3)

The method of claim 3, wherein the measuring comprises contacting the sample with a VEGF-D antibody under conditions that allow binding of the antibody to VEGF-D in the sample.

### Claim 19 (depends on 3)

The method of claim 3, wherein the biological sample comprises serum.

### Claim 20 (depends on 3)

The method of claim 3, wherein LAM is selected from the group consisting of tuberous sclerosis complex lymphangioleiomyomatosis (TSC-LAM) and non-heritable sporadic form lymphangioleiomyomatosis (S-LAM).

### Claim 21 (depends on 3)

The method of claim 3, wherein the subject is female.

### Claim 22 (depends on 3)

The method of claim 3, wherein the standard of care therapeutic is selected from the group consisting of hormone therapy, oxygen therapy, pleurodesis, embolization, ablation or resection of angiomyolipomas; bronchodilator therapy, withdrawal from estrogen-containing medications, thoracic duct ligation, oophorectomy and lung transplantation.

### Claim 23 (depends on 4)

The method of claim 4, wherein the measuring comprises contacting the sample with a VEGF-D antibody under conditions that allow binding of the antibody to VEGF-D in the sample.

### Claim 24 (depends on 4)

The method of claim 4, wherein the biological sample comprises serum.

### Claim 25 (depends on 4)

The method of claim 4, wherein LAM is selected from the group consisting of tuberous sclerosis complex lymphangioleiomyomatosis (TSC-LAM) and non-heritable sporadic form lymphangioleiomyomatosis (S-LAM).

### Claim 26 (depends on 4)

The method of claim 4, wherein the subject is female.

### Claim 27 (depends on 4)

The method of claim 4, wherein the standard of care therapeutic is selected from the group consisting of hormone therapy, oxygen therapy, pleurodesis, embolization, ablation or resection of angiomyolipomas; bronchodilator therapy, withdrawal from estrogen-containing medications, thoracic duct ligation, oophorectomy and lung transplantation.
